In 2010, cholera was introduced in Haiti, resulting in over 800,000 cases of cholera and over 10,000 deaths. While the cholera epidemic in Haiti is the largest in over 25 years, it is far from an isolated event, and other large outbreaks have occurred in South Sudan, Sierra Leone, Tanzania, the Democratic Republic of the Congo, Iraq, Nigeria and most recently in Yemen where over 860,000 cases of cholera have occurred 2017. In addition to these epidemics, cholera is currently endemic in 47 countries where it often disproportionately occurs in young children. When cholera was introduced in Haiti, vaccination was not considered part of the standard public health response to cholera epidemics. During the first funding period of this project we showed that a new, lower-cost oral cholera vaccination was highly immunogenic in children and adults in Haiti, and that vaccination was feasible and effective in preventing cholera in Haiti. These studies have contributed to an improved understanding of cholera vaccines, which are now being deployed globally to more effectively prevent large cholera epidemics. Despite this progress in understanding cholera vaccines, there remains an urgent need to learn more about how to eliminate cholera in areas once it is already established in the environment. In this proposal, we address questions that will improve upon current programs to eliminate human cholera transmission in such endemic areas.
Our aims will leverage public health activities undertaken by our team and partners, including an innovative cholera elimination program in Haiti which will include vaccination with household water treatment and safe storage interventions. In this study, we will use novel methods to understand how both symptomatic and asymptomatic breakthrough cholera infections occur even after an intervention to eliminate cholera. We will also determine whether such integrated vaccination and water related interventions impact more broadly on the health of young children in the community. We will do this by looking at their nutritional health, intestinal health, and infection with specific intestinal bacteria, and seeing how these relate to vaccination and improvements in water quality at the household level. Given our team?s experience in Haiti, our involvement in providing cholera treatment and prevention services, our multidisciplinary scientific approach, and our contribution to global cholera policy, we are well poised to address these critical questions, which are urgently needed to inform the most effective approach toward achieving the World Health Organization?s goal of the elimination of cholera transmission as a global threat by 2030.

Public Health Relevance

Assessing measures to eliminate cholera in Haiti will inform future public health strategies to eliminate the threat of cholera transmission globally. This project will also improve our understanding of how cholera elimination programs may broadly impact on the health of young children beyond their effect on cholera alone.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
Hall, Robert H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Richterman, Aaron; Cheung, Hoi Ching; Meiselbach, Mark K et al. (2018) Risk Factors for Self-Reported Cholera Within HIV-Affected Households in Rural Haiti. Open Forum Infect Dis 5:ofy127
Bourque, Daniel L; Bhuiyan, Taufiqur Rahman; Genereux, Diane P et al. (2018) Analysis of the Human Mucosal Response to Cholera Reveals Sustained Activation of Innate Immune Signaling Pathways. Infect Immun 86:
Levade, Inès; Terrat, Yves; Leducq, Jean-Baptiste et al. (2017) Vibrio cholerae genomic diversity within and between patients. Microb Genom 3:
Mayo-Smith, Leslie M; Simon, Jakub K; Chen, Wilbur H et al. (2017) The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae. Clin Vaccine Immunol 24:
Matias, Wilfredo R; Teng, Jessica E; Hilaire, Isabelle J et al. (2017) Household and Individual Risk Factors for Cholera among Cholera Vaccine Recipients in Rural Haiti. Am J Trop Med Hyg 97:436-442
Franke, Molly F; Jerome, J Gregory; Matias, Wilfredo R et al. (2017) Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design. Vaccine 35:5819-5827
Kauffman, Robert C; Bhuiyan, Taufiqur R; Nakajima, Rie et al. (2016) Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells. MBio 7:
Matias, Wilfredo R; Falkard, Brie; Charles, Richelle C et al. (2016) Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults. PLoS Negl Trop Dis 10:e0004753
Koski-Karell, Victoria; Farmer, Paul E; Isaac, Benito et al. (2016) Haiti's progress in achieving its 10-year plan to eliminate cholera: hidden sickness cannot be cured. Risk Manag Healthc Policy 9:87-100
Harris, Jason B; LaRocque, Regina C (2016) Cholera and ABO Blood Group: Understanding an Ancient Association. Am J Trop Med Hyg 95:263-4

Showing the most recent 10 out of 27 publications